cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15151/esrf-es-1424926448
title: High temperature superconducting oxychlorides : a light element model for magnetic excitations in cuprates.

description: Para-magnons are considered one of the possible bosons leading to Cooper pairing in cuprates. However, theory has long failed to describe the electronic state of doped cuprates, as they are difficult to treat with calculations that incorporate correlations. We are currently doing detailed first-principle calculations in oxychloride cuprates, including techniques that explicitly incorporate the electron-electron interactions and that are particularly well suited for our case. We will complete our study of paramagnons in oxychlorides, at the highest doping, in order to maximize the effect of the mobile charges on the magnetic excitation, as well as very low doping, in the pure pseudo-gap phase, in order to compare the results with our calculations.
DOI: 10.6084/m9.figshare.25026770
title: For GRS analysis.xlsx

description: The data is of acute lymphoblastic leukemia patients and was used for the evaluation of genetic risk score.
DOI: 10.6084/m9.figshare.25026770.v1
title: For GRS analysis.xlsx

description: The data is of acute lymphoblastic leukemia patients and was used for the evaluation of genetic risk score.
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000470
title: mass spectrometry (MS) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for mass spectrometry (MS)
 
 MS (EI, 70 eV, 20 °C), m/z (%): 185 (100) [M]+, 170 (25), 142 (35). HRMS–EI (C12H11ON) (m/z): [M]+ Calcd 185.0835; Found 185.0836.
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000599
title: correlation spectroscopy (COSY) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for correlation spectroscopy (COSY)
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n.1
title: 2-(4-methoxyphenyl)pyridine
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367].
 The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]:
 InChI descriptor[cheminf_000113]: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3, and canonical SMILES descriptor[cheminf_000007]: COc1ccc(cc1)c1ccccn1, and by the IUPAC name[cheminf_000107]: 2-(4-methoxyphenyl)pyridine.
 
 The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]:
 
 The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-38518

 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]:
 Melting point descriptor[CHEMINF_000256]: 50.5 - 53.3 (°C)
 Boiling point descriptor[CHEMINF_000257]: 
 Refractive index descriptor[CHEMINF_000253]:

 The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]:
 
 CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR)
 
 CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR)
 
 CHMO:0000470 | mass spectrometry (MS)
 
 CHMO:0000596 | distortionless enhancement with polarization transfer (DEPT)
 
 CHMO:0000630 | infrared absorption spectroscopy (IR)
 
 CHMO:0000596 | distortionless enhancement with polarization transfer (DEPT)
 
 CHMO:0000604 | heteronuclear single quantum coherence (HSQC)
 
 CHMO:0000601 | heteronuclear multiple bond coherence (HMBC)
 
 CHMO:0000599 | correlation spectroscopy (COSY)
 
 The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: 

 Used ontologies:
 CHEBI - Chemical Entities of Biological Interest
 CHEMINF - chemical information ontology (information entities about chemical entities)
 CHMO - Chemical Methods Ontology
 OBI - Ontology for Biomedical Investigations
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000596
title: distortionless enhancement with polarization transfer (DEPT) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR)
 
 1H NMR (400 MHz, Chloroform-d [7.26 ppm], ppm) δ = 8.66 (ddd, J = 4.8 Hz, J = 1.5 Hz, J = 0.9 Hz, 1H), 7.98–7.95 (m, 2H), 7.73–7.66 (m, 2H), 7.17 (ddd, J = 6.9 Hz, J = 4.8 Hz, J = 1.3 Hz, 1H), 7.03–6.99 (m, 2H), 3.87 (s, 3H).
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000596.1
title: distortionless enhancement with polarization transfer (DEPT) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000601
title: heteronuclear multiple bond coherence (HMBC) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for heteronuclear multiple bond coherence (HMBC)
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000604
title: heteronuclear single quantum coherence (HSQC) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for heteronuclear single quantum coherence (HSQC)
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for infrared absorption spectroscopy (IR)
 
 IR (ATR, ṽ) = 3050 (w), 2996 (m), 2961 (w), 2936 (w), 2915 (w), 2836 (w), 1601 (m), 1579 (s), 1561 (m), 1513 (s), 1459 (s), 1431 (s), 1303 (m), 1272 (m), 1242 (vs), 1176 (vs), 1152 (s), 1112 (s), 1057 (m), 1035 (s), 1020 (vs), 1006 (s), 987 (s), 973 (m), 837 (vs), 805 (m), 776 (vs), 737 (vs), 717 (vs), 637 (m), 620 (m), 578 (s), 555 (s), 526 (m), 487 (s), 418 (m), 399 (s), 377 (w) cm–1.
DOI: 10.14272/qumxrznaufkbas-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) (2-(4-methoxyphenyl)pyridine)
title: InChI=1S/C12H11NO/c1-14-11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR)
 
 13C NMR (100 MHz, Chloroform-d [77.0 ppm], ppm) δ = 160.4 (Cq), 157.1 (Cq), 149.5 (CH), 136.6 (CH), 132.0 (Cq), 128.1 (2C, CH), 121.4 (CH), 119.8 (CH), 114.1 (2C, CH), 55.3 (CH3).
DOI: 10.5281/zenodo.10531640
title: SORUNLARLA İSLAMİYET - HAYATIN İÇİNDEN FIKIH

description: SORUNLARLA İSLAMİYET - HAYATIN İÇİNDEN GERÇEK SORUNLARA İSLAMİ BAKIŞ AÇISIYLA FIKHİ ÇÖZÜMLER
DOI: 10.5281/zenodo.10531652
title: Dataset related to article "Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)""

description: Abstract



 Background:  Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28-02-2023], after first online publication: 'humanized monoclonal antibody' has been changed to 'fully human monoclonal antibody' in the preceding sentence.] OBJECTIVES: We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting.

 Methods:  Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered.

 Results:  At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI ≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study.

 Conclusion:  Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in 'real-life' clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.
DOI: 10.5281/zenodo.10531651
title: Dataset related to article "Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)""

description: Abstract



 Background:  Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28-02-2023], after first online publication: 'humanized monoclonal antibody' has been changed to 'fully human monoclonal antibody' in the preceding sentence.] OBJECTIVES: We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting.

 Methods:  Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered.

 Results:  At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI ≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study.

 Conclusion:  Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in 'real-life' clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.
DOI: 10.25345/c5bz61k50
title: MassIVE MSV000093891 - Oxidative Cyclization Reagents Reveal Tryptophan Cation-pi interactions
title: Raw data of the project "Oxidative Cyclization Reagents Reveal Tryptophan Cation-pi interactions"
DOI: 10.6084/m9.figshare.25026794
title: 无题项目

description: <b>Biological sciences</b>
DOI: 10.6084/m9.figshare.25026794.v1
title: 无题项目

description: <b>Biological sciences</b>
DOI: 10.6084/m9.figshare.25027079
title: Data

description: The data files contains price/return values of various assets.
DOI: 10.21227/d6ng-f856
title: EventGO System Tasks

description: The automatic extraction of meetup event information from the Internet can substantially enhance the ease of discovering activities. However, when event organizers share event details across various platforms, including their respective websites, social media, and specialized event-listing sites, different types of events may be distributed across multiple channels. Consequently, users are often compelled to search through various avenues to find events in which they are interested.In this study, we propose a cost-effective framework for mining events from event organizers' websites instead of crawling the entire web. We begin by utilizing Facebook Events and event-based social networks to identify potential event-organizer websites and extract webpages containing the latest news listings from these sites. Subsequently, we apply unsupervised data-extraction techniques to segment the input pages into individual messages. Finally, we conduct structured event extraction to extract event information from the individual message pages. Our experimental results, obtained between July 13, 2023, and November 22, 2023, indicate that our event-mining framework successfully collected 7,012 web scraping APIs by automatically identifying URLs on the Web. Among 429,266 published links on message source pages, 134,902 messages are acquired following boilerplate removal. Subsequently, 33,988 event messages are identified by the event-detection module. Finally, the event-extraction module extracts 33,577 events.
DOI: 10.6084/m9.figshare.25027088
title: Prognostic factors influencing survival in patients with advanced HER-2 positive breast cancer

description: A retrospective analysis was conducted using the medical records of 90 patients with advanced breast cancer admitted to our hospital from January 2018 to March 2023. Patients were divided into death group (n=66) and survival group (n=24). Logistic regression analysis was employed to examine the risk factors associated with survival in patients with advanced breast cancer. Cox regression analysis was utilized to identify independent prognostic factors affecting the 5-year survival of patients.
DOI: 10.6084/m9.figshare.25027088.v1
title: Prognostic factors influencing survival in patients with advanced HER-2 positive breast cancer

description: A retrospective analysis was conducted using the medical records of 90 patients with advanced breast cancer admitted to our hospital from January 2018 to March 2023. Patients were divided into death group (n=66) and survival group (n=24). Logistic regression analysis was employed to examine the risk factors associated with survival in patients with advanced breast cancer. Cox regression analysis was utilized to identify independent prognostic factors affecting the 5-year survival of patients.
DOI: 10.6084/m9.figshare.24751686.v1
title: The mystery of phospho-Drp1 with four adaptors in cell cycle: when mitochondrial fission couples to cell fate decisions

description: Recent study had deepened our knowledge of the mitochondrial dynamics to classify mitochondrial fission into two types. To further clarify the relationship between the two distinct fission machinery and the four major adaptors of Drp1, we propose a model of mechanism elucidating the multiple functions of phospho-Drp1 with its adaptors during cell cycle and providing in-depth insights into the molecular basis and evolutionary implications in depth. The model highlights not only the clustering characteristics of different phospho-Drp1 with respective subsets of mitochondrial pro-fission adaptors but also the correlation, crosstalk and shifting between different clustering of phosphorylated Drp1-adaptors during different key fission situations. Particularly, phospho-Drp1 (Ser616) couples with Mff/MiD51 to exert mitochondrial division and phospho-Drp1 (Ser637) couples with MiD49/Fis1 to execute mitophagy in M-phase. We then apply the model to address the relationship of mitochondrial dynamics to Parkinson’s disease (PD) and carcinogenesis. Our proposed model is indeed compatible with current research results and pathological observations, providing promising directions for future treatment design.
DOI: 10.6084/m9.figshare.24891978
title: High-density lipoprotein protects vascular endothelial cells from indoxyl sulfate insults through its antioxidant ability

description: Chronic kidney disease (CKD) patients have a high risk of cardiovascular disease. Indoxyl sulfate (IS) is a uremic toxin that has been shown to inhibit nitric oxide production and cause cell senescence by inducing oxidative stress. High-density lipoprotein (HDL) has a protective effect on the cardiovascular system; however, its impacts on IS-damaged endothelial cells are still unknown. This study aimed to explore the effects of exogenous supplement of HDL on vascular endothelial cells in a uremia-mimic environment. Tube formation, migration, adhesion, and senescence assays were used to evaluate the cell function of human aortic endothelial cells (HAECs). Reactive oxygen species generation was measured by using Amplex red assay. L-NAME and MCI186 were used as a nitric oxide synthase inhibitor and a free radical scavenger, respectively. HDL exerted anti-inflammatory and antioxidant effects via HIF-1α/HO-1 activation and IL-1β/TNF-α/IL-6 inhibition in IS-stimulated HAECs. HDL improved angiogenesis ability through upregulating Akt/eNOS/VEGF/SDF-1 in IS-stimulated HAECs. HDL decreased endothelial adhesiveness via downregulating VCAM-1 and ICAM-1 in IS-stimulated HAECs. Furthermore, HDL reduced cellular senescence via upregulating SIRT1 and downregulating p53 in IS-stimulated HAECs. Importantly, the above beneficial effects of HDL were mainly due to its antioxidant ability. In conclusion, HDL exerted a comprehensive protective effect on vascular endothelial cells against damage from IS through its antioxidant ability. The results of this study might provide a theoretical basis for potential HDL supplementation in CKD patients with endothelial damage.
DOI: 10.6084/m9.figshare.24891978.v1
title: High-density lipoprotein protects vascular endothelial cells from indoxyl sulfate insults through its antioxidant ability

description: Chronic kidney disease (CKD) patients have a high risk of cardiovascular disease. Indoxyl sulfate (IS) is a uremic toxin that has been shown to inhibit nitric oxide production and cause cell senescence by inducing oxidative stress. High-density lipoprotein (HDL) has a protective effect on the cardiovascular system; however, its impacts on IS-damaged endothelial cells are still unknown. This study aimed to explore the effects of exogenous supplement of HDL on vascular endothelial cells in a uremia-mimic environment. Tube formation, migration, adhesion, and senescence assays were used to evaluate the cell function of human aortic endothelial cells (HAECs). Reactive oxygen species generation was measured by using Amplex red assay. L-NAME and MCI186 were used as a nitric oxide synthase inhibitor and a free radical scavenger, respectively. HDL exerted anti-inflammatory and antioxidant effects via HIF-1α/HO-1 activation and IL-1β/TNF-α/IL-6 inhibition in IS-stimulated HAECs. HDL improved angiogenesis ability through upregulating Akt/eNOS/VEGF/SDF-1 in IS-stimulated HAECs. HDL decreased endothelial adhesiveness via downregulating VCAM-1 and ICAM-1 in IS-stimulated HAECs. Furthermore, HDL reduced cellular senescence via upregulating SIRT1 and downregulating p53 in IS-stimulated HAECs. Importantly, the above beneficial effects of HDL were mainly due to its antioxidant ability. In conclusion, HDL exerted a comprehensive protective effect on vascular endothelial cells against damage from IS through its antioxidant ability. The results of this study might provide a theoretical basis for potential HDL supplementation in CKD patients with endothelial damage.
DOI: 10.6084/m9.figshare.24751686
title: The mystery of phospho-Drp1 with four adaptors in cell cycle: when mitochondrial fission couples to cell fate decisions

description: Recent study had deepened our knowledge of the mitochondrial dynamics to classify mitochondrial fission into two types. To further clarify the relationship between the two distinct fission machinery and the four major adaptors of Drp1, we propose a model of mechanism elucidating the multiple functions of phospho-Drp1 with its adaptors during cell cycle and providing in-depth insights into the molecular basis and evolutionary implications in depth. The model highlights not only the clustering characteristics of different phospho-Drp1 with respective subsets of mitochondrial pro-fission adaptors but also the correlation, crosstalk and shifting between different clustering of phosphorylated Drp1-adaptors during different key fission situations. Particularly, phospho-Drp1 (Ser616) couples with Mff/MiD51 to exert mitochondrial division and phospho-Drp1 (Ser637) couples with MiD49/Fis1 to execute mitophagy in M-phase. We then apply the model to address the relationship of mitochondrial dynamics to Parkinson’s disease (PD) and carcinogenesis. Our proposed model is indeed compatible with current research results and pathological observations, providing promising directions for future treatment design.
DOI: 10.6084/m9.figshare.24288062
title: Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis

description: The current study aimed to evaluate the cost-effectiveness of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in China. A partitioned survival model was established to track 3-week patients’ transition and project the health and economic outputs in 15-year horizon of the two competing options among sintilimab and docetaxel. Clinical data were obtained from the ORIENT-3 trial, and cost and utility values were gathered from the local charges and published studies. Total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were evaluated. Sensitivity analyses were conducted to assess the robustness of the model outcomes. Base-case results revealed that sintilimab yield marginal cost of $4,700.53 and additional 0.32 QALYs, resulting in an ICER of $14,615.31 per QALY gained, which is lower than the willingness-to-pay threshold of $38,224/QALY in China. One-way sensitivity analyses showed that the cost of best supportive care was the main driver of the ICER, and probabilistic sensitivity analyses demonstrated that the model outputs were robust. Sintilimab could be considered the cost-effective second-line strategy for patients with advanced or metastatic squamous NSCLC compared with docetaxel in China.